Sales Across All Product Categories Increase; Margins Expand as High-Ticket
                       Epilepsy System Sales Accelerate

    MUNDELEIN, Ill., June 30 /PRNewswire/ -- Bio-logic Systems Corp.
(Nasdaq: BLSC), a designer and marketer of computerized medical
electrodiagnostic equipment, today reported significant progress in its
operating results.  In its first quarter ended May 31, 1999, the company began
to realize the benefits of extensive work last year in upgrading all product
software to a Windows-based platform, advancing its epilepsy technology,
introducing new products, further developing its physician-specialist customer
base and penetrating the general practitioner market.
    "We are very pleased with the level of orders we are generating across all
product lines -- neurology, audiology and sleep disorders.  We invested
substantial resources of time and money last year to produce one of the
leading product offerings in the industry in terms of technology, efficiency
and diversity," said Dr. Gabriel Raviv, president and chief executive officer.
"Our new, digital 64/128-channel epilepsy monitoring system, Ceegraph XL,
incorporates the most advanced technology  available today.  Demand for this
higher-quality system with broader diagnostic capabilities is driving larger
orders and supporting increased margins.  We are one of only a few competitors
offering a 128-channel system.  This gives us a distinct advantage because
hospitals and physicians looking to invest in an EEG system want to initiate a
long-term partnership with a manufacturer that can continue to upgrade their
systems as their needs grow.
    "In addition to contributions from new and upgraded EEG products, our
financial performance also benefited from a large order from the Far East,"
said Dr. Raviv.  "This order, which was written in the fourth quarter and
shipped in the first quarter, was a major contribution that led to a 100
percent increase in international sales.  While we are encouraged by these
sales, we remain cautious about any rebound overseas.  It's still too early to
tell if this buying activity is the beginning of a trend, or simply an
isolated action."
    Sales for the fiscal 2000 first quarter increased 69 percent to
$6.3 million compared with $3.7 million in the similar fiscal 1999 quarter.
Domestic sales rose 64 percent, and international sales increased 100 percent
from a year earlier.  Operating expenses as a percent of sales declined nearly
24 percent in the latest three months.  Similar to the fourth quarter, the
stronger sales and only a modest increase in operating expenses led to a
substantially improved bottom line.  Net income was $705,629, or $0.18 per
basic and diluted share, compared with a net loss of $217,963, or $0.05 per
share, a year ago.
    Investments to support new product sales will be an important focus for
Bio-logic over the next three quarters.  The company expects to increase its
number of sales representatives, and hire additional customer support and
service personnel and equipment technicians.
    "The launch of our 64/128-channel EEG system represents an excellent
opportunity to capitalize on a competitive advantage to rapidly gain a greater
share of the $30 million U.S. epilepsy market.  In  doing so, we want to make
sure sales of our superior products are backed by seamless installation,
comprehensive customer training and accurate usage.  This may mean outfitting
each major customer with an onsite engineer to oversee a project from start to
finish.  We've already done this for Boston Children's Hospital, where we have
a $1.4 million contract for our complete neurodiagnostic system, and the
installation and activation process is proceeding very smoothly," said
Dr. Raviv.
    Bio-logic's audiology product sales are progressing and the company
expects to roll out a complementary product to the line later this year.
Sleepscan products have now been upgraded to Windows and the company is
beginning to ship the converted systems, while continuing to add value to the
software by creating more features.

    Financial Position
    The company's cash and marketable securities increased to $5.9 million at
May 31, 1999, from $5.2 million a year earlier.  Long-term debt as a percent
of capitalization decreased to 8.4 percent, and the current ratio was 5 to 1.
Shareholders' equity increased to $13.4 million from $12.2 million at May 31,
1998.
    Bio-logic Systems Corp., headquartered in Mundelein, Ill., designs,
develops, assembles and markets computer-based electrodiagnostic systems for
use by hospitals, clinics, universities and physicians.  The systems conduct
tests that are typically used by medical practitioners to aid in the diagnosis
of certain neurological, psychiatric and sensory disorders, psychological and
learning disorders, brain disorders and tumors.

    Safe Harbor Statement
    Except for descriptions of historical facts, this release contains
forward-looking statements that involve known and unknown risks, which may
cause the company's actual results in the future to differ materially from
those currently anticipated.  These risks include, among others, fluctuations
in sales and operating results; risks associated with international operations
including monetary crisis; regulatory, competitive, and contractual risks; the
effects of economic conditions; any delays or additional costs associated with
the marketing of the AuDX(R) product; and the availability of capital to
finance planned growth, as well as other risks detailed from time to time in
the company's filings with the Securities and Exchange Commission.

    To receive Bio-logic's latest news release and other corporate documents,
free of charge via fax, simply dial 1-800-PRO-INFO.  Use company ticker BLSC.


                        BIO-LOGIC SYSTEMS CORPORATION
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (Unaudited)

                                               Three Months Ended
                                                    May 31,
                                            1999                1998

    NET SALES                           $6,278,284          $3,707,314
    COST OF SALES                        1,996,924           1,227,154
        Gross Profit                     4,281,360           2,480,160

    OPERATING EXPENSES:
     Selling, general & administrative   2,668,385           2,114,661
     Research & development                683,520             747,203
       Total Operating Expenses          3,351,905           2,861,864

    OPERATING INCOME (LOSS)                929,455            (381,704)

    OTHER INCOME (EXPENSE):
     Interest Income                        58,527              64,652
     Interest expense                       (7,424)             (9,350)
     Miscellaneous                            (529)               (861)

    INCOME (LOSS) BEFORE
     INCOME TAXES                          980,029            (327,263)

    PROVISION (BENEFIT) FOR
     INCOME TAXES                          274,400            (109,300)

    NET INCOME (LOSS)                      705,629            (217,963)

    EARNINGS PER SHARE:
     Basic and Diluted                       $0.18              ($0.05)

    WEIGHTED AVERAGE SHARES
     OUTSTANDING
      Basic                              3,995,036           3,988,592
      Diluted                            4,025,180           3,988,592


                         SELECTED BALANCE SHEET DATA
                                         May 31,              May 31,
                                           1999                 1998

    Cash and marketable securities      $5,900,183          $5,170,002
    Current assets                      14,127,653          12,072,670
    Total assets                        16,721,555          14,946,999
    Current liabilities                  2,850,271           2,023,727
    Long term obligations                  257,987             391,818
    Shareholders' equity                13,368,402          12,237,906

Link to this page: